Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated:  2/24/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Randomized Phase II Trial of Pre-Operative Docetaxel-Cytoxan (TC) or Exemestane in Patients With Hormone Receptor-Positive Breast Cancers With Recurrence Scores Greater Than 10 (≥ 11) and Less Than 25 (≤ 24)
Status: Enrolling
Updated: 2/24/2017
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ
A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ
Status: Enrolling
Updated:  2/27/2017
Erin Hofstatter, MD
mi
from
New Haven, CT
A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ
A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ
Status: Enrolling
Updated: 2/27/2017
Erin Hofstatter, MD
mi
from
New Haven, CT
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Scottsdale, AZ
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Tucson, AZ
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Santa Monica, CA
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Washington,
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Washington,
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Fort Myers, FL
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Atlanta, GA
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Detroit, MI
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Lebanon, NH
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Buffalo, NY
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Durham, NC
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Durham, NC
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Cleveland, OH
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Greenville, SC
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Memphis, TN
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Nashville, TN
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Salt Lake City, UT
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Edmonton,
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Edmonton,
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University of Alabama Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University of Michigan
mi
from
Ann Arbor, MI
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Baylor College of Medicine
mi
from
Houston, TX
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
ZNA Middelheim
mi
from
Antwerpen,
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
ZNA Middelheim
mi
from
Antwerpen,
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University Of Alabama Comprehensive Cancer Cente
mi
from
Birmingham, AL
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University Of Alabama Comprehensive Cancer Cente
mi
from
Birmingham, AL
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
UCSF University of California San Francisco Medical Center-Mount Zion
mi
from
San Francisco, CA
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
UCSF University of California San Francisco Medical Center-Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
University of Chicago Medicine
mi
from
Chicago, IL
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Johns Hopkins University CRB1
mi
from
Baltimore, MD
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Johns Hopkins University CRB1
mi
from
Baltimore, MD
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Memorial Sloan-Kettering Cancer Center - Memorial hospital
mi
from
New York, NY
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Memorial Sloan-Kettering Cancer Center - Memorial hospital
mi
from
New York, NY
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Baylor College - Ucop
mi
from
Houston, TX
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Baylor College - Ucop
mi
from
Houston, TX
Click here to add this to my saved trials
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated:  2/28/2017
Fred Hutchison Seattle Cancer Care Alliance
mi
from
Seattle, WA
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Clinical and Biological Characterization of Male Breast Cancer: an International EORTC, BIG, TBCRC and NABCG Intergroup Study.
Status: Enrolling
Updated: 2/28/2017
Fred Hutchison Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Massachusetts General Hospital Mass Gen 3
mi
from
Boston, MA
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Massachusetts General Hospital Mass Gen 3
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Cancer Institute of New Jersey SC
mi
from
New Brunswick, NJ
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Cancer Institute of New Jersey SC
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson
mi
from
Philadelphia, PA
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
University of Utah / Huntsman Cancer Institute Huntsman 3
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
University of Wisconsin Clinical Science Center
mi
from
Madison, WI
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
University of Wisconsin Clinical Science Center
mi
from
Madison, WI
Click here to add this to my saved trials
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated:  2/28/2017
Novartis Investigative Site
mi
from
Bruxelles,
Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer
Status: Enrolling
Updated: 2/28/2017
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Muscle Shoals, AL
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Corona, CA
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Corona, CA
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Riverside, CA
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Metairie, LA
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Rockville, MD
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated:  2/28/2017
Clinical Research Facility
mi
from
Howell, NJ
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen
Status: Enrolling
Updated: 2/28/2017
Clinical Research Facility
mi
from
Howell, NJ
Click here to add this to my saved trials